Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Thomas Clozel is the co-founder and CEO of Owkin, a French-American AI biotechnology company that uses artificial intelligence and federated learning to discover and develop better treatments for patients. With a background as a clinical research doctor and former assistant professor in clinical hematology, Dr. Clozel transitioned into entrepreneurship to leverage AI's potential in revolutionizing medical research and drug development. He holds an MD from Paris Descartes University and a PhD in Health Economics. His vision is to build a global research network through Owkin, connecting leading academic institutions and pharmaceutical companies to accelerate therapeutic innovation while prioritizing patient data privacy and security.
Thomas Clozel's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
Successfully co-founded Owkin in 2016, building it into a leading AI biotechnology company focused on discovering and developing new drugs and diagnostic tools to improve patient outcomes using AI and federated learning.
Championed the application of federated learning in medical research, enabling collaborative AI model training on distributed datasets without moving sensitive patient data, thereby enhancing privacy and security.
Led Owkin through significant funding rounds, including a notable investment from Sanofi, and established strategic collaborations with major pharmaceutical companies (like BMS, Amgen) and research institutions worldwide.
Driving Owkin's mission to use AI to identify new drug targets, predict treatment efficacy, and optimize clinical trial design, contributing to the acceleration of bringing new therapies to patients.
Recognized for his contributions to AI in healthcare and entrepreneurship, including features in prominent industry publications and leadership forums discussing the future of medicine.
Weill Medical College of Cornell University - Year 2009
Mount Sinai School of Medicine of New York University - Year 2006
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
OWKIN is an AI biotechnology company that specializes in using artificial intelligence and machine learning, particularly federated learning, for medical research and drug discovery. They aim to connect the global healthcare ecosystem, enabling researchers to securely analyze vast amounts of patient data from different institutions without data centralization, thus preserving patient privacy. OWKIN's platforms and services help to identify new drug targets, develop diagnostic tools, predict treatment outcomes, and accelerate clinical trials, ultimately aiming to improve patient care and bring precision medicine to reality.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.